# FDA Adverse Event Reporting System (FAERS) Data - Q1 2025

## Overview

The FDA Adverse Event Reporting System (FAERS) is a database that contains information on adverse event and medication error reports submitted to FDA. The database is designed to support the FDA's post-marketing safety surveillance program for drug and therapeutic biologic products.

## Data Source

- **Source**: Food and Drug Administration (FDA)
- **Dataset**: FAERS Q1 2025 ASCII format data file
- **Download URL**: https://fis.fda.gov/content/Exports/faers_ascii_2025q1.zip
- **File Size**: 64.3MB
- **Date Posted**: April 28, 2025

## Data Contents

The FAERS quarterly data files include:

1. Demographic and administrative information
2. Drug information from the case reports
3. Reaction information from the reports
4. Patient outcome information from the reports
5. Information on the source of the reports

## GLP-1 Receptor Agonist Adverse Events

This dataset would contain adverse event reports related to GLP-1 receptor agonist medications, including:

- Semaglutide (Ozempic, Wegovy, Rybelsus)
- Liraglutide (Victoza, Saxenda)
- Dulaglutide (Trulicity)
- Tirzepatide (Mounjaro, Zepbound)
- Exenatide (Byetta, Bydureon)
- Lixisenatide (Adlyxin)

## Data Format

The data files are in ASCII format and require familiarity with relational databases for analysis. The dataset consists of several tables that can be linked together to view complete adverse event reports.

## Note About Access

The complete raw data files require specialized database knowledge to analyze properly. For specific GLP-1 receptor agonist adverse event data, a formal Freedom of Information Act (FOIA) request to the FDA would provide more accessible summary information.

This file serves as documentation for the FAERS data file which contains adverse event information related to GLP-1 receptor agonists and other medications.